Bio-Techne Corporation logo
TECHBio-Techne Corporation

Interest Coverage Ratio: 23.43x

Is the interest coverage ratio high or low?

The interest coverage ratio of 23.43x is in line with its 5-year average of 21.51x, around the middle of its 5-year range (-10.96x–58.68x).

As of Saturday, June 27, 2026. 60.29% above its 12-month average of 14.62x.

Interest Coverage

TECH Interest Coverage Ratio

23.43x

Reported quarterly interest coverage; no daily interpolation.

+12.44% 5Y
TECH Interest Coverage Ratio

TECH Average Interest Coverage Ratio Chart

TECH Interest Coverage Ratio

TECH Current vs Average Interest Coverage Ratio Chart

TECH Interest Coverage Ratio Metrics

INTEREST COVERAGE RATIO

23.43x

INTEREST COVERAGE RATIO AVG TTM

14.62x

INTEREST COVERAGE RATIO AVG 3Y

18.66x

INTEREST COVERAGE RATIO AVG 5Y

21.26x

INTEREST COVERAGE RATIO AVG 10Y

16.31x

INTEREST COVERAGE RATIO AVG 15Y

N/A

INTEREST COVERAGE RATIO AVG 20Y

N/A

CURRENT VS TTM AVG

+60.29%

CURRENT VS 3Y AVG

+25.59%

CURRENT VS 5Y AVG

+10.19%

CURRENT VS 10Y AVG

+43.64%

CURRENT VS 15Y AVG

N/A

CURRENT VS 20Y AVG

N/A

TECH Competitors' Interest Coverage Ratio

NAMEMARKET CAPINTEREST COVERAGE RATIOTTM3Y5Y
Bio-Techne Corporation (TECH)$11.12B23.43x14.62x18.66x21.26x
Insulet Corp. (PODD)vs ›$10.96B5.94x6.59x5.07x3.90x
Baxter International Inc. (BAX)vs ›$11.38B-1.06x0.71x2.65x6.89x
Molina Healthcare, Inc. (MOH)vs ›$11.79B4.07x9.27x11.38x10.77x
Walgreens Boots Alliance, Inc. (WBA)vs ›$10.37B-29.20x3.03x3.75x5.52x
Charles River Laboratories International, Inc. (CRL)vs ›$10.20B4.74x3.27x5.51x5.84x
Tempus AI, Inc. (TEM)vs ›$9.80B-3.40xN/AN/AN/A
Henry Schein, Inc. (HSIC)vs ›$9.68B5.05x5.30x10.04x14.14x
Revvity, Inc. (RVTY)vs ›$12.61B3.87x4.06x4.92x8.88x
Align Technology, Inc. (ALGN)vs ›$12.78BN/A67.41x66.08x407.22x

Financial Health Indicators

Interest Coverage

23.4x

Debt/Equity

0.23

Current Ratio

3.46

Formula: Interest Coverage = EBIT / Interest Expense

Reference ranges:

  • < 1.5x: EBIT is less than 1.5 times interest expense
  • 1.5x - 3x: EBIT is between 1.5 and 3 times interest expense
  • 3x - 5x: EBIT is between 3 and 5 times interest expense
  • > 5x: EBIT is more than 5 times interest expense

Note: Interest coverage should be compared with historical interest expense, operating income, and industry capital structure.

Interest Coverage Ratio Formula & Definition

Interest Coverage = EBIT / Interest Expense

The interest coverage ratio measures operating earnings relative to interest expense.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

Interest Coverage Ratio FAQ

What is the interest coverage ratio for Bio-Techne Corporation (TECH)?
The interest coverage ratio for TECH stock is 23.43x.
Is Bio-Techne Corporation's interest coverage ratio high or low?
The interest coverage ratio of 23.43x is in line with its 5-year average of 21.51x, around the middle of its 5-year range (-10.96x–58.68x).
What is the TTM average interest coverage ratio for Bio-Techne Corporation (TECH)?
The TTM average interest coverage ratio for TECH stock is 14.62x.
What is the 3Y average interest coverage ratio for Bio-Techne Corporation (TECH)?
The 3Y average interest coverage ratio for TECH stock is 18.66x.
What is the 5Y average interest coverage ratio for Bio-Techne Corporation (TECH)?
The 5Y average interest coverage ratio for TECH stock is 21.26x.
What is the 10Y average interest coverage ratio for Bio-Techne Corporation (TECH)?
The 10Y average interest coverage ratio for TECH stock is 16.31x.

TECH Interest Coverage Ratio History

DATEINTEREST COVERAGE RATIO
2026-03-3123.43x
2025-12-3125.09x
2025-09-3016.24x
2025-06-30-10.96x
2025-03-3119.29x
2024-12-3122.08x
2024-09-3018.38x
2024-06-3018.26x
2024-03-3116.73x
2023-12-318.78x
2023-09-3011.42x
2023-06-3025.53x
2023-03-3158.68x
2022-12-3128.82x
2022-09-3014.86x
2022-06-3032.16x
2022-03-3136.28x
2021-12-3121.48x
2021-09-3018.55x
2021-06-3020.84x
2021-03-3125.80x
2020-12-3114.22x
2020-09-3011.12x
2020-06-308.51x
2020-03-3110.65x
2019-12-317.59x
2019-09-306.38x
2019-06-307.73x
2019-03-318.62x
2018-12-315.83x
2018-09-304.92x
2018-06-3014.06x
2018-03-3116.83x
2017-12-3110.36x
2017-09-3011.61x
2017-06-3019.20x
2017-03-3115.32x
2016-12-318.40x
2016-09-3018.17x
2016-06-3092.41x
2016-03-3197.16x
2015-12-3190.06x
2015-09-3068.80x
2015-06-3097.43x
2015-03-3195.23x
2014-12-3179.13x
2014-09-30113.23x

About Bio-Techne Corporation

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Spatial Biology. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies. This segment also offers proteomic analytical tools for automated western blot and multiplexed ELISA workflow consists of manual and automated protein analysis instruments and immunoassays for use in quantifying proteins in various biological fluids. The Diagnostics and Genomics segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for regulated diagnostics market, exosome-based molecular diagnostic assays, advanced tissue-based in-situ hybridization assays for spatial genomic and tissue biopsy analysis, and genetic and oncology kits for research and clinical applications; and sells products for genetic carrier screening, oncology diagnostics, molecular controls, and research, as well as instruments and process control products for hematology, blood chemistry and gases, and coagulation controls and reagents used in various diagnostic applications. The company was formerly known as Techne Corporation and changed its name to Bio-Techne Corporation in November 2014. Bio-Techne Corporation was incorporated in 1976 and is headquartered in Minneapolis, Minnesota.

Minneapolis, MN
3,100 employees
Healthcare / Biotechnology
Sector
Healthcare
Industry
Biotechnology
CEO
Kim Kelderman